Mantle cell lymphoma historical perspective: Difference between revisions

	Mantle cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Mantle cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mantle cell lymphoma historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mantle cell lymphoma historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mantle cell lymphoma historical perspective
on Mantle cell lymphoma historical perspective
Mantle cell lymphoma historical perspective in the news
Blogs on Mantle cell lymphoma historical perspective
Directions to Hospitals Treating Mantle cell lymphoma
Risk calculators and risk factors for Mantle cell lymphoma historical perspective

Revision as of 18:44, 5 November 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

In 1964, Lennert first described the disease as 'centrocytic' lymphoma.
In 1992, Banks first coined the term Mantle Cell Lymphoma (MCL) and in 1994, MCL was included into the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification.

The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].

There have been several outbreaks of [disease name], which are summarized below:

In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].

The following are a few famous cases of disease name:

@@ Line 9: / Line 9: @@
 ===Discovery===
-*In 1964, Lennert first described the disease as centrocytic lymphoma.
+*In 1964, Lennert first described the disease as 'centrocytic' lymphoma.
-*In 1992, Banks first coined the term Mantle Cell Lymphoma (MCL). In 1994, MCL was included into the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification.
+*In 1992, Banks first coined the term Mantle Cell Lymphoma (MCL) and in 1994, MCL was included into the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification.
 *The association between [important risk factor/cause] and [disease name] was made in/during [year/event].